Investigators are reeling from the news that desmoteplase, a novel thrombolytic derived from vampire-bat saliva, showed no benefit in a phase 3 trial comparing 2 different doses with placebo. Mortality was actually increased with the higher dose of the thrombolytic, although the excess was not attributed to treatment.
Medscape Medical News
Susan Jeffrey
More...